Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

t2c 001

Next Previous
Drug Profile

t2c 001

Alternative Names: Autologous bone marrow-derived mononuclear cell fraction; t2c001; t2c001-AMI; t2c001-CHD; t2c001-DCM; t2c001-SW

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator t2cure
  • Class Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cardiomyopathies; Heart failure; Ischaemic heart disorders; Myocardial infarction; Thromboangiitis obliterans

Most Recent Events

  • 28 Jul 2015 No recent reports on development identified - Phase-I/II for Cardiomyopathy, Heart failure, Ischaemic heart disorders and Thromboangiitis obliterans in Germany (Intra-arterial)
  • 28 Jul 2015 No recent reports on development identified - Phase-II for Myocardial infarction in Germany (Intra-arterial)
  • 20 Sep 2010 t2c 001 receives Orphan Drug status for Thromboangiitis obliterans in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top